<unk>  is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma.  A study has shown that<unk>  produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with<unk>  versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in<unk>  arm. The main toxicity was grade 3 to 4 neutropenia (51% with<unk>  v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).
Fotemustine
Bendamustine
Lomustine
Estramustine
Carmustine 
Prednimustine
Idoxuridine
Floxuridine